ABEONA THERAPEUTICS INC. Insider Trading Activity

Abeona Therapeutics director Donald A. Wuchterl reported receiving 37,313 shares of common stock as restricted stock on January 26, 2026, at a price of $0.00 per share.

Accepted by SEC EDGAR 01/27/2026 - 04:30 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Abeona Therapeutics director Donald A. Wuchterl reported receiving 37,313 shares of common stock as restricted stock on January 26, 2026, at a price of $0.00 per share. After this grant, he directly holds 182,749 shares of Abeona common stock.

According to the filing, all of this restricted stock will vest on January 26, 2027, meaning the shares become fully owned by him on that date if the vesting conditions are met.

Insider Trade Summary

Grant/Award: 37,313 shares

Grant/Award 1 txn

Insider Wuchterl Donald A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	37,313	$0.00	$0.00

Holdings After Transaction: Common Stock — 182,749 shares (Direct)

Holdings Before and After: Common Stock, 145,436 to 182,749 shares (Direct)

Footnotes (1)

F1. All of the restricted stock will vest on January 26, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ABEO director Donald Wuchterl report?

Donald Wuchterl reported receiving 37,313 shares of Abeona Therapeutics common stock as restricted stock. The grant was recorded at a price of $0.00 per share and increases his directly held stake in the company to 182,749 common shares following the transaction.

When do Donald Wuchterl's new ABEO restricted shares vest?

All 37,313 restricted shares granted to Donald Wuchterl vest on January 26, 2027. Vesting means the shares become fully owned at that date, assuming conditions are met, turning this grant into unrestricted common stock at that time.

How many ABEO shares does Donald Wuchterl own after this Form 4?

After the reported transaction, Donald Wuchterl beneficially owns 182,749 shares of Abeona Therapeutics common stock directly. This total reflects the addition of 37,313 restricted shares granted on January 26, 2026, as disclosed in the Form 4 filing.

What type of security was reported in this ABEO Form 4 filing?

The filing reports a grant of common stock in the form of restricted shares. A total of 37,313 restricted common shares were awarded at $0.00 per share, with all of them scheduled to vest on January 26, 2027, for director Donald Wuchterl.

What was the transaction code used in Donald Wuchterl's ABEO Form 4?

The transaction used code "A," indicating an acquisition of securities. In this case, 37,313 shares of Abeona Therapeutics common stock were acquired as a restricted stock grant, reported at a price of $0.00 per share, and held directly afterward.

Is Donald Wuchterl a 10% owner of Abeona Therapeutics?

The Form 4 identifies Donald Wuchterl as a director of Abeona Therapeutics but not as a 10% owner. Only the director box is checked, while the 10% owner box is not, indicating his role is board-related rather than based on crossing that ownership threshold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wuchterl Donald A.

(Last)

(First)

(Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND

44103

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/26/2026		A		37,313⁽¹⁾	A	$0.00	182,749	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Donald A. Wuchterl	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR